SCHEMBL4934962

SCHEMBL4934962

Nc1ccc2[nH]c(C(=O)NCCN3CCOCC3)c(-c3ccccc3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 2/20 0.55
CD274 Q9NZQ7 2/20 0.53
HPGD P15428 1/20 0.53
TP53 P04637 1/20 0.52
MDM2 Q00987 1/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 1/20 0.51
KMT2A Q03164 1/20 0.51
MMP12 P39900 1/20 0.50
WNT1 P04628 1/20 0.49
DYRK1A Q13627 1/20 0.49
PARP1 P09874 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
HPGDS O60760 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930087 0.85 KMT2A (0.63) MDM4CD274HPGDTP53MDM2
SCHEMBL3943442 0.84 ALDH1A1 (0.47) MDM4CD274HPGDALDH1A1KDM4E
SCHEMBL4926259 0.80 ALDH1A1 (0.56) HPGDALDH1A1KDM4EHSD17B10KMT2A
SCHEMBL3950606 0.79 HSD17B10 (0.49) HPGDALDH1A1KDM4EHSD17B10LMNA
SCHEMBL5151439 0.78 ALDH1A1 (0.49) MDM4CD274HPGDTP53MDM2
SCHEMBL3943840 0.78 ALDH1A1 (0.47) MDM4CD274HPGDTP53MDM2
SCHEMBL4926916 0.78 ALDH1A1 (0.53) HPGDTP53ALDH1A1KDM4EHSD17B10
SCHEMBL39935 0.78 ALDH1A1 (0.62) MDM4HPGDTP53MDM2ALDH1A1
SCHEMBL14307300 0.77 ALDH1A1 (0.46) MDM4CD274HPGDTP53MDM2
SCHEMBL14383477 0.77 BACE1 (0.50) MDM4CD274HPGDTP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 MDM4 4860/4885CD274 4795/4885HPGD 135/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 MDM4 4860/4885CD274 4795/4885HPGD 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.